OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A– Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B- Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and…
Surinder Kaur, Stephen C. Alley, Matt Szapacs, et al.
Bioanalysis (2022) Vol. 14, Iss. 9, pp. 505-580
Closed Access | Times Cited: 18
Surinder Kaur, Stephen C. Alley, Matt Szapacs, et al.
Bioanalysis (2022) Vol. 14, Iss. 9, pp. 505-580
Closed Access | Times Cited: 18
Showing 18 citing articles:
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization)
Johanna Mora, Rachel Palmer, Leslie Wagner, et al.
Bioanalysis (2024) Vol. 16, Iss. 7, pp. 77-119
Closed Access | Times Cited: 6
Johanna Mora, Rachel Palmer, Leslie Wagner, et al.
Bioanalysis (2024) Vol. 16, Iss. 7, pp. 77-119
Closed Access | Times Cited: 6
Absolute quantitation of binding antibodies from clinical samples
Chan Tang, Annemiek Verwilligen, Jerald Sadoff, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Chan Tang, Annemiek Verwilligen, Jerald Sadoff, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Immunocapture LC–MS Methods for Pharmacokinetics of Large Molecule Drugs
Emily G. Werth, David Roos, Elsy Philip
Bioanalysis (2024) Vol. 16, Iss. 7, pp. 165-177
Open Access | Times Cited: 3
Emily G. Werth, David Roos, Elsy Philip
Bioanalysis (2024) Vol. 16, Iss. 7, pp. 165-177
Open Access | Times Cited: 3
2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies)
Olga Kholmanskikh, Yow‐Ming Wang, Sarah Hersey, et al.
Bioanalysis (2024) Vol. 16, Iss. 8, pp. 179-220
Open Access | Times Cited: 3
Olga Kholmanskikh, Yow‐Ming Wang, Sarah Hersey, et al.
Bioanalysis (2024) Vol. 16, Iss. 8, pp. 179-220
Open Access | Times Cited: 3
Advances and opportunities in process analytical technologies for viral vector manufacturing
Sobhana A. Sripada, Mahshid Hosseini, Srivatsan Ramesh, et al.
Biotechnology Advances (2024) Vol. 74, pp. 108391-108391
Closed Access | Times Cited: 3
Sobhana A. Sripada, Mahshid Hosseini, Srivatsan Ramesh, et al.
Biotechnology Advances (2024) Vol. 74, pp. 108391-108391
Closed Access | Times Cited: 3
2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization
Giane Sumner, Steve Keller, James W. Huleatt, et al.
Bioanalysis (2023) Vol. 15, Iss. 15, pp. 861-903
Closed Access | Times Cited: 10
Giane Sumner, Steve Keller, James W. Huleatt, et al.
Bioanalysis (2023) Vol. 15, Iss. 15, pp. 861-903
Closed Access | Times Cited: 10
2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)
Luying Pan, Johanna Mora, Karl Walravens, et al.
Bioanalysis (2023) Vol. 15, Iss. 14, pp. 773-814
Closed Access | Times Cited: 9
Luying Pan, Johanna Mora, Karl Walravens, et al.
Bioanalysis (2023) Vol. 15, Iss. 14, pp. 773-814
Closed Access | Times Cited: 9
2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A – Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, …
Matt Szapacs, Wenying Jian, Daniel S. Spellman, et al.
Bioanalysis (2023) Vol. 15, Iss. 16, pp. 955-1016
Closed Access | Times Cited: 9
Matt Szapacs, Wenying Jian, Daniel S. Spellman, et al.
Bioanalysis (2023) Vol. 15, Iss. 16, pp. 955-1016
Closed Access | Times Cited: 9
Bioanalytical Strategy for the Characterization and Bioanalysis of Biologics: A Global, Nonregulated Bioanalytical Lab Perspective
Hetal Sarvaiya, Shuai Niu, Daniel T. Ladror, et al.
Bioanalysis (2023) Vol. 15, Iss. 3, pp. 133-148
Closed Access | Times Cited: 6
Hetal Sarvaiya, Shuai Niu, Daniel T. Ladror, et al.
Bioanalysis (2023) Vol. 15, Iss. 3, pp. 133-148
Closed Access | Times Cited: 6
Enhanced Pharmacokinetic Bioanalysis of Antibody–drug Conjugates using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS
Moo‐Jin Suh, Joshua B. Powers, Casey M. Daniels, et al.
The AAPS Journal (2023) Vol. 25, Iss. 4
Closed Access | Times Cited: 4
Moo‐Jin Suh, Joshua B. Powers, Casey M. Daniels, et al.
The AAPS Journal (2023) Vol. 25, Iss. 4
Closed Access | Times Cited: 4
Criteria of Slope and Endogenous Level for Selection of Matrix in the Quantitation of Endogenous Compounds by LC-MS/MS
Allena Ji, Guangxin Xu, Lin Tao, et al.
Bioanalysis (2022) Vol. 14, Iss. 11, pp. 807-816
Open Access | Times Cited: 5
Allena Ji, Guangxin Xu, Lin Tao, et al.
Bioanalysis (2022) Vol. 14, Iss. 11, pp. 807-816
Open Access | Times Cited: 5
Expanding Assay Range to Accommodate a Monoclonal Antibody Therapeutic Quantification in Blood and Cerebrospinal Fluid
Alejandro R. Foley, Gizette Sperinde, Saloumeh K Fischer
Bioanalysis (2023) Vol. 16, Iss. 3, pp. 129-140
Closed Access | Times Cited: 2
Alejandro R. Foley, Gizette Sperinde, Saloumeh K Fischer
Bioanalysis (2023) Vol. 16, Iss. 3, pp. 129-140
Closed Access | Times Cited: 2
A novel biomarker assay qualification strategy for rare human matrices – a case study of biomarkers in aqueous humor
Jennifer A. Getz, Trung Nguy, Randall C. Dere, et al.
Bioanalysis (2024) Vol. 16, Iss. 8, pp. 239-247
Closed Access
Jennifer A. Getz, Trung Nguy, Randall C. Dere, et al.
Bioanalysis (2024) Vol. 16, Iss. 8, pp. 239-247
Closed Access
2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/…
Mike Baratta, Wenying Jian, Shawna Hengel, et al.
Bioanalysis (2024) Vol. 16, Iss. 9, pp. 307-364
Closed Access
Mike Baratta, Wenying Jian, Shawna Hengel, et al.
Bioanalysis (2024) Vol. 16, Iss. 9, pp. 307-364
Closed Access
Inclusion of dilution quality control samples in quantitative LC-MS bioanalysis
Wenkui Li, Yunlin Fu, Franck Picard
Bioanalysis (2024), pp. 1-3
Closed Access
Wenkui Li, Yunlin Fu, Franck Picard
Bioanalysis (2024), pp. 1-3
Closed Access
The quantitative and qualitative measurement of 2022: Bioanalysis volume 15
Jack Lodge
Bioanalysis (2023) Vol. 15, Iss. 1, pp. 1-4
Closed Access
Jack Lodge
Bioanalysis (2023) Vol. 15, Iss. 1, pp. 1-4
Closed Access
Validation of a method for itraconazole and major metabolite hydroxyitraconazole for LC-MS/MS analysis with application in a formulation clinical study
Samuel A. Krug, Ana Luisa Coutinho, James E. Polli, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 234, pp. 115505-115505
Open Access
Samuel A. Krug, Ana Luisa Coutinho, James E. Polli, et al.
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 234, pp. 115505-115505
Open Access
Bioanalysis Considerations for CAR T-Cell Therapies
Jinping Lai, Jing Shi
Genetic Engineering & Biotechnology News (2022) Vol. 42, Iss. 11, pp. 38-40
Closed Access
Jinping Lai, Jing Shi
Genetic Engineering & Biotechnology News (2022) Vol. 42, Iss. 11, pp. 38-40
Closed Access
